Alectinib vs Brigatinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline

Alectinib · Alecensa

Marketed by Roche and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02075840 · Phase 3 · completed

Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 (From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)): Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019). (met)

Result source: NCT02838420

Brigatinib

Marketed by Takeda Pharmaceutical Company

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02737501 · Phase 3 · completed

This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT04223596 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months (missed)

Result source: NCT03596866

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlectinibBrigatinib
PFS, median10.9 vs 1.4vs Premetrexed/Docetaxeln 79NCT02604342
5 other results
  • 25.7 vs 10.4 n 152 · Phase 3 · secondary NCT02075840
  • 7.1 vs 1.6 n 72 · Phase 3 · secondary NCT02604342
  • 8.2 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.4 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.9 n 138 · Phase 1/2 · secondary NCT01801111
24.0 vs 11.1vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
10 other results
  • 19.3 vs 19.2 n 125 · Phase 3 · primary NCT03596866
  • 16.8 vs 16.6 n 125 · Phase 3 · secondary NCT03596866
  • 9.2 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 15.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 12.6 90 mg QD · n 15 · Phase 1/2 · secondary NCT01449461
  • 11 90 mg QD-180 mg QD · n 21 · Phase 1/2 · secondary NCT01449461
  • 5.4 180 mg QD/90 mg BID · n 40 · Phase 1/2 · secondary NCT01449461
  • 5.4 240 mg QD/120 mg BID/300 mg QD · n 7 · Phase 1/2 · secondary NCT01449461
  • 5.4 120 mg QD/60 mg BID · n 17 · Phase 1/2 · secondary NCT01449461
  • 1.8 30 mg QD/60 mg QD · n 5 · Phase 1/2 · secondary NCT01449461
OS, median81.1 vs 54.2vs Crizotinibn 152NCT02075840
3 other results
25.9b90 mg · n 112NCT02094573
8 other results
  • 40.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 21.3 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
  • 11.6 90 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 17.9 90 mg QD-180 mg QD · n 17 · Phase 1/2 · secondary NCT01449461
  • 8.3 240 mg QD/120 mg BID/300 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 7.3 180 mg QD/90 mg BID · n 25 · Phase 1/2 · secondary NCT01449461
  • 7.3 120 mg QD/60 mg BID · n 12 · Phase 1/2 · secondary NCT01449461
  • 5.3 30 mg QD/60 mg QD · n 6 · Phase 1/2 · secondary NCT01449461
ORR82.9% vs 75.5%vs Crizotinibn 152NCT02075840
9 other results
74.5% vs 62.3%vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
6 other results
  • 45.5% 90 mg · n 112 · Phase 2 · primary NCT02094573
  • 57.3% 90 mg - 180 mg · n 110 · Phase 2 · primary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · primary NCT03535740
  • 51.8% 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 56.4% 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
Duration of response, median42.3 vs 11.1vs Crizotinibn 126NCT02075840
3 other results
  • 14.9 600 mg (Fed) · n 35 · Phase 1/2 · secondary NCT01871805
  • 13.3 600 mg (Fed) · n 46 · Phase 1/2 · secondary NCT01871805
  • 15.2 n 62 · Phase 1/2 · secondary NCT01801111
33.1 vs 13.8vs Crizotinib90 mg QD/180 QD · n 102NCT02737501
2 other results
  • 12 90 mg · n 51 · Phase 2 · secondary NCT02094573
  • 13.8 90 mg - 180 mg · n 63 · Phase 2 · secondary NCT02094573

PFS, median

Alectinib
10.9 vs 1.4vs Premetrexed/Docetaxeln 79NCT02604342
5 other results
  • 25.7 vs 10.4 n 152 · Phase 3 · secondary NCT02075840
  • 7.1 vs 1.6 n 72 · Phase 3 · secondary NCT02604342
  • 8.2 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.4 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.9 n 138 · Phase 1/2 · secondary NCT01801111
Brigatinib
24.0 vs 11.1vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
10 other results
  • 19.3 vs 19.2 n 125 · Phase 3 · primary NCT03596866
  • 16.8 vs 16.6 n 125 · Phase 3 · secondary NCT03596866
  • 9.2 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 15.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 12.6 90 mg QD · n 15 · Phase 1/2 · secondary NCT01449461
  • 11 90 mg QD-180 mg QD · n 21 · Phase 1/2 · secondary NCT01449461
  • 5.4 180 mg QD/90 mg BID · n 40 · Phase 1/2 · secondary NCT01449461
  • 5.4 240 mg QD/120 mg BID/300 mg QD · n 7 · Phase 1/2 · secondary NCT01449461
  • 5.4 120 mg QD/60 mg BID · n 17 · Phase 1/2 · secondary NCT01449461
  • 1.8 30 mg QD/60 mg QD · n 5 · Phase 1/2 · secondary NCT01449461

OS, median

Alectinib
81.1 vs 54.2vs Crizotinibn 152NCT02075840
3 other results
Brigatinib
25.9b90 mg · n 112NCT02094573
8 other results
  • 40.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 21.3 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
  • 11.6 90 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 17.9 90 mg QD-180 mg QD · n 17 · Phase 1/2 · secondary NCT01449461
  • 8.3 240 mg QD/120 mg BID/300 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 7.3 180 mg QD/90 mg BID · n 25 · Phase 1/2 · secondary NCT01449461
  • 7.3 120 mg QD/60 mg BID · n 12 · Phase 1/2 · secondary NCT01449461
  • 5.3 30 mg QD/60 mg QD · n 6 · Phase 1/2 · secondary NCT01449461

ORR

Alectinib
82.9% vs 75.5%vs Crizotinibn 152NCT02075840
9 other results
Brigatinib
74.5% vs 62.3%vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
6 other results
  • 45.5% 90 mg · n 112 · Phase 2 · primary NCT02094573
  • 57.3% 90 mg - 180 mg · n 110 · Phase 2 · primary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · primary NCT03535740
  • 51.8% 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 56.4% 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740

Duration of response, median

Alectinib
42.3 vs 11.1vs Crizotinibn 126NCT02075840
3 other results
  • 14.9 600 mg (Fed) · n 35 · Phase 1/2 · secondary NCT01871805
  • 13.3 600 mg (Fed) · n 46 · Phase 1/2 · secondary NCT01871805
  • 15.2 n 62 · Phase 1/2 · secondary NCT01801111
Brigatinib
33.1 vs 13.8vs Crizotinib90 mg QD/180 QD · n 102NCT02737501
2 other results
  • 12 90 mg · n 51 · Phase 2 · secondary NCT02094573
  • 13.8 90 mg - 180 mg · n 63 · Phase 2 · secondary NCT02094573
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. Alectinib: 11 of 11 rows · Brigatinib: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlectinib
Rows use multiple source trials
Brigatinib
Rows use multiple source trials
CNS ORR
responder rate · % of participants
No placebo or comparator arm
58.8% (n=34)a,b,c,d,e
NCT01801111 · Phase 1/2
show 1 more dose
44.1% (n=34)
NCT01801111 · Phase 1/2
47.4% (n=19)90 mga,b,c,d,e
NCT02094573 · Phase 2
show 3 more doses
12.1% (n=33)90 mg
NCT02094573 · Phase 2
73.3% (n=15)90 mg - 180 mg
NCT02094573 · Phase 2
16.7% (n=36)90 mg - 180 mg
NCT02094573 · Phase 2
Disease Control
responder rate · % of participants
82.7% (n=52) vs 25% (n=28) Premetrexed/Docetaxelf,d,e
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
85.4% (n=137) vs 86.2% (n=138) Crizotinib90 mg QD/180 QDf,d,e
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
Disease Control
responder rate · % of participants
No placebo or comparator arm
66.7% (n=87)600 mg (Fed)b,c,d,e
NCT01871805 · Phase 1/2 · registry result, not featured evidence
81.3% (n=112)90 mga,b,c,d,e
NCT02094573 · Phase 2
show 1 more dose
86.4% (n=110)90 mg - 180 mg
NCT02094573 · Phase 2
Duration of Response
time to event · months
No placebo or comparator arm
15.2 monthsb,c,d,e
NCT01801111 · Phase 1/2
2 other source trials
14.9 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
13.3 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
12 months90 mga,b,c,d,e
NCT02094573 · Phase 2
show 1 more dose
13.8 months90 mg - 180 mg
NCT02094573 · Phase 2
ORR
responder rate · % of participants
No placebo or comparator arm
50.8% (n=122)a,b,c,d,e
NCT01801111 · Phase 1/2
show 5 more doses
44.8% (n=96)
NCT01801111 · Phase 1/2
73.1% (n=26)
NCT01801111 · Phase 1/2
51.4% (n=138)
NCT01801111 · Phase 1/2
50% (n=110)
NCT01801111 · Phase 1/2
57.1% (n=28)
NCT01801111 · Phase 1/2
45.5% (n=112)90 mga,b,c,d,e
NCT02094573 · Phase 2
show 3 more doses
51.8% (n=112)90 mg
NCT02094573 · Phase 2
57.3% (n=110)90 mg - 180 mg
NCT02094573 · Phase 2
56.4% (n=110)90 mg - 180 mg
NCT02094573 · Phase 2
Overall Survival
time to event · months
No placebo or comparator arm
29.2 monthsb,c,d,e
NCT01801111 · Phase 1/2
1 other source trial
27.9 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
25.9 months90 mga,b,c,d,e
NCT02094573 · Phase 2
show 1 more dose
40.6 months90 mg - 180 mg
NCT02094573 · Phase 2
PFS
time to event · months
No placebo or comparator arm
8.9 monthsb,c,d,e
NCT01801111 · Phase 1/2
2 other source trials
8.2 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
8.4 months600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
9.2 months90 mga,b,c,d,e
NCT02094573 · Phase 2
show 1 more dose
15.6 months90 mg - 180 mg
NCT02094573 · Phase 2
Dropout rate
n/a: no completion milestoneg
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
n/a: no completion milestone
NCT02838420 · Phase 3 · monotherapy
54.4%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT01801111 · Phase 1/2
—600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
85.4%90 mg QD/180 QDh
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
97.6%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone90 mg
NCT02094573 · Phase 2
n/a: no completion milestone90 mg - 180 mg
NCT02094573 · Phase 2
—90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
—240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
0%g
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
—
NCT02838420 · Phase 3 · monotherapy
—
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
8.7%
NCT01801111 · Phase 1/2
—600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
—90 mg QD/180 QDh
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
—
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3.6%90 mg
NCT02094573 · Phase 2
12.7%90 mg - 180 mg
NCT02094573 · Phase 2
—90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
—240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
3.8%90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
16.7%90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
9.4%90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
26.7%240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
8.3%180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
11.1%120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
0%30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
Serious AEs
46.1%g
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
15.2%
NCT02838420 · Phase 3 · monotherapy
26%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
28.3%
NCT01801111 · Phase 1/2
24.1%600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
41.2%90 mg QD/180 QDh
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
30.4%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
53.2%90 mg
NCT02094573 · Phase 2
62.7%90 mg - 180 mg
NCT02094573 · Phase 2
46.6%90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
23.1%240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
35.6%90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
55.6%90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
43.8%90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
73.3%240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
62.5%180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
55.6%120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
16.7%30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
g
constipation 40.1%
anaemia 27.6%
blood bilirubin increased 24.3%
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
aspartate aminotransferase increased 52%
blood bilirubin increased 48.8%
blood creatine phosphokinase increased 44%
NCT02838420 · Phase 3 · monotherapy
constipation 20.8%
anaemia 15.6%
myalgia 14.3%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
constipation 38.4%
fatigue 31.2%
oedema peripheral 30.4%
NCT01801111 · Phase 1/2
600 mg (Fed)
fatigue 41.4%
constipation 39.1%
headache 28.7%
NCT01871805 · Phase 1/2 · registry result, not featured evidence
90 mg QD/180 QDh
diarrhoea 57.4%
blood creatine phosphokinase increased 50%
cough 36%
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
blood creatine phosphokinase increased 73.6%
aspartate aminotransferase increased 56.8%
alanine aminotransferase increased 47.2%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
90 mg
nausea 43.1%
vomiting 40.4%
headache 35.8%
NCT02094573 · Phase 2
90 mg - 180 mg
nausea 50%
diarrhoea 46.4%
cough 40.9%
NCT02094573 · Phase 2
90/180 mg
diarrhoea 39.8%
blood creatine phosphokinase increased 34%
nausea 28.2%
NCT03535740 · Phase 2 · registry result, not featured evidence
240 mg
diarrhoea 53.8%
blood creatine phosphokinase increased 38.5%
aspartate aminotransferase increased 23.1%
NCT03535740 · Phase 2 · registry result, not featured evidence
90 mg/180 mg
blood creatine phosphokinase increased 77.9%
hypertension 47.1%
diarrhoea 45.2%
NCT03410108 · Phase 2 · registry result, not featured evidence
90 mg QD
fatigue 50%
diarrhoea 44.4%
headache 44.4%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
90 mg QD-180 mg QD
diarrhoea 53.1%
fatigue 50%
nausea 50%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
240 mg QD/120 mg BID/300 mg QD
fatigue 80%
cough 53.3%
diarrhoea 53.3%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
180 mg QD/90 mg BID
nausea 68.8%
diarrhoea 43.8%
fatigue 39.6%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
120 mg QD/60 mg BID
fatigue 50%
nausea 50%
aspartate aminotransferase increased 38.9%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
30 mg QD/60 mg QD
abdominal pain 50%
nausea 50%
electrocardiogram qt prolonged 33.3%
NCT01449461 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 1/2 versus Phase 2.
  3. cPopulation context differs: registered conditions differ.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation context differs: registered conditions differ; prior_therapy differs (experienced versus naive).
  7. gPopulation comparability has not been reviewed for 3 of these studies.
  8. hPopulation comparability has not been reviewed for 11 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alectinib

CNS Progression 11.8% (n=152) vs 45% (n=151) Crizotinib
responder rate · % of participants
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
10.5% (n=152) vs 35.8% (n=151) Crizotinib
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS ORR 59.4% (n=152) vs 25.9% (n=151) Crizotinib
responder rate · % of participants
Measurable and non-measurable CNS lesions
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS DOR 17.3 vs 5.5 Crizotinib months
absolute value · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration C30 Dyspnoea NA vs NA Crizotinib months
time to event · months
Dyspnea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration LC13 Cough NA vs NA Crizotinib months
time to event · months
Coughing
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Dyspnea 22.8 vs NA Crizotinib months
time to event · months
Dyspnea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration LC13 Chest Pain NA vs NA Crizotinib months
time to event · months
Pain in chest
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Composite Symptoms 12.7 vs 21 Crizotinib months
time to event · months
Composite score (c, p in c, d)
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
LC13 Deterioration 32% (n=152) vs 28% (n=151) Crizotinib
ratio to baseline · % of baseline
Composite score (c, p in c, d)
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS ORR 66.7% (n=24) vs 0% (n=17) Premetrexed/Docetaxel
responder rate · % of participants
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
ORR 36.1% (n=79) vs 11.4% (n=40) Premetrexed/Docetaxel
responder rate · % of participants
Assessed by IRC
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Disease Control 76.4% (n=79) vs 48.6% (n=40) Premetrexed/Docetaxel
responder rate · % of participants
Assessed by IRC
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3

+ 624 further endpoints in the CSV export.

Brigatinib

Intracranial ORR 66% (n=47) vs 14.3% (n=49) Crizotinib90 mg QD/180 QD
responder rate · % of participants
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 1 more result
73.3% (n=30) vs 67.7% (n=31) Alectinib
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial PFS 23.951 vs 5.52 Crizotinib months90 mg QD/180 QD
absolute value · months
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
Time to Response 1.84 vs 1.873 Crizotinib months90 mg QD/180 QD
time to event · months
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-C30 GHS 4.007 vs -4.088 Crizotinib score @ 144wk90 mg QD/180 QD
absolute change · score
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
ORR 52% (n=125) vs 61% (n=123) Alectinib
responder rate · % of participants
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Duration of Response 17.544 vs 20.205 Alectinib months
time to event · months
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Response 1.873 vs 1.84 Alectinib months
time to event · months
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial Duration of Response 17.413 vs NA Alectinib months
time to event · months
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Cumulative Incidence Intracranial Progression 0.115 vs 0.076 Alectinib probability @ 26wk
absolute value · probability
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
0.218 vs 0.171 Alectinib probability @ 52wk
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.305 vs 0.209 Alectinib probability @ 78wk
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.388 vs 0.248 Alectinib probability @ 104wk
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial PFS 12.8 months90 mg
absolute value · months
No placebo or comparator arm
NCT02094573 · Phase 2
show 7 more results
12.8 months90 mg - 180 mg
NCT02094573 · Phase 2
5.224 months90 mg/180 mg With Optional Dose Escalation to 240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
36.8 months90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
NA months90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
7.3 months240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
14.4 months180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
6.7 months120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
Time to Response 1.8 months90 mg
time to event · months
No placebo or comparator arm
NCT02094573 · Phase 2
show 1 more result
1.9 months90 mg - 180 mg
NCT02094573 · Phase 2
Duration of Response 6.341 months90 mg/180 mg With Optional Dose Escalation to 240 mg
time to event · months
No placebo or comparator arm
IRC-Assessed DOR
NCT03535740 · Phase 2 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · Brigatinib's landscape